The case, docketed on January 8, 2026, as Case No. 2:26-cv-01542, pulls in three insulin producers — Eli Lilly and Firm, Novo Nordisk Inc., and Sanofi-Aventis U.S. LLC – alongside the pharmacy profit administration operations of Cigna Well being and Life Insurance coverage Firm, Evernorth Well being, Inc. (previously Specific Scripts Holding Firm) and associates, CVS Well being Company and its Caremark subsidiaries, and UnitedHealth Group, Inc. by Optum and OptumRx, amongst others. New Haven, which runs self-insured well being plans for its workers and eligible retirees, says it has been paying artificially inflated costs for insulin and different diabetes medication consequently.
